Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 185 | 2024 | 16183 | 3.090 |
Why?
|
Receptors, Estrogen | 64 | 2024 | 2158 | 1.720 |
Why?
|
Tamoxifen | 30 | 2020 | 875 | 1.520 |
Why?
|
Antineoplastic Agents, Hormonal | 25 | 2021 | 841 | 1.320 |
Why?
|
Receptor, ErbB-2 | 35 | 2023 | 2650 | 1.240 |
Why?
|
Receptors, Progesterone | 30 | 2021 | 1603 | 0.920 |
Why?
|
Mammary Glands, Animal | 17 | 2022 | 620 | 0.920 |
Why?
|
Gene Expression Profiling | 41 | 2021 | 5138 | 0.900 |
Why?
|
Estrogen Receptor alpha | 17 | 2021 | 692 | 0.870 |
Why?
|
Mammary Neoplasms, Experimental | 22 | 2017 | 551 | 0.850 |
Why?
|
Drug Resistance, Neoplasm | 32 | 2024 | 5405 | 0.790 |
Why?
|
Triple Negative Breast Neoplasms | 10 | 2024 | 1391 | 0.770 |
Why?
|
Oligonucleotide Array Sequence Analysis | 26 | 2014 | 2472 | 0.730 |
Why?
|
Signal Transduction | 45 | 2021 | 12087 | 0.720 |
Why?
|
Gene Expression Regulation, Neoplastic | 45 | 2021 | 9039 | 0.720 |
Why?
|
Female | 241 | 2024 | 148486 | 0.690 |
Why?
|
Genomics | 7 | 2018 | 2834 | 0.670 |
Why?
|
Mammary Neoplasms, Animal | 6 | 2022 | 236 | 0.640 |
Why?
|
Quinazolines | 16 | 2023 | 956 | 0.620 |
Why?
|
Humans | 302 | 2024 | 270033 | 0.600 |
Why?
|
Cell Line, Tumor | 56 | 2024 | 14832 | 0.590 |
Why?
|
Information Dissemination | 4 | 2014 | 266 | 0.590 |
Why?
|
Estradiol | 17 | 2020 | 828 | 0.570 |
Why?
|
Mice | 101 | 2024 | 35465 | 0.570 |
Why?
|
Bayes Theorem | 3 | 2024 | 1058 | 0.560 |
Why?
|
Biomarkers, Tumor | 36 | 2024 | 10695 | 0.550 |
Why?
|
Mammary Tumor Virus, Mouse | 13 | 2018 | 144 | 0.550 |
Why?
|
Animals | 122 | 2024 | 61714 | 0.540 |
Why?
|
Cell Proliferation | 33 | 2024 | 7236 | 0.540 |
Why?
|
Genetic Testing | 7 | 2017 | 1695 | 0.530 |
Why?
|
Transcription Factor AP-1 | 9 | 2016 | 248 | 0.520 |
Why?
|
STAT5 Transcription Factor | 5 | 2022 | 226 | 0.500 |
Why?
|
Models, Statistical | 5 | 2018 | 1185 | 0.500 |
Why?
|
Antineoplastic Agents | 34 | 2023 | 14615 | 0.490 |
Why?
|
Estrogens | 12 | 2020 | 808 | 0.470 |
Why?
|
Xenograft Model Antitumor Assays | 20 | 2024 | 3911 | 0.460 |
Why?
|
Cell Transformation, Neoplastic | 17 | 2022 | 2448 | 0.450 |
Why?
|
Data Interpretation, Statistical | 2 | 2012 | 483 | 0.440 |
Why?
|
Genetic Counseling | 2 | 2018 | 417 | 0.440 |
Why?
|
Taxoids | 12 | 2017 | 1016 | 0.430 |
Why?
|
Precancerous Conditions | 7 | 2018 | 1033 | 0.430 |
Why?
|
Epithelial Cells | 13 | 2022 | 1867 | 0.420 |
Why?
|
Cyclin-Dependent Kinase 6 | 2 | 2024 | 135 | 0.400 |
Why?
|
Cyclin-Dependent Kinase 4 | 2 | 2024 | 210 | 0.390 |
Why?
|
Biomedical Research | 3 | 2021 | 794 | 0.380 |
Why?
|
Neoplastic Stem Cells | 9 | 2015 | 1456 | 0.380 |
Why?
|
Receptors, G-Protein-Coupled | 5 | 2021 | 485 | 0.380 |
Why?
|
Neoplasm Metastasis | 16 | 2021 | 5309 | 0.370 |
Why?
|
Tetrahydronaphthalenes | 6 | 2009 | 114 | 0.370 |
Why?
|
Gene Expression | 13 | 2020 | 3630 | 0.370 |
Why?
|
Neoplasms | 19 | 2024 | 15902 | 0.370 |
Why?
|
Trastuzumab | 14 | 2023 | 743 | 0.360 |
Why?
|
Prognosis | 59 | 2021 | 22451 | 0.360 |
Why?
|
Apoptosis | 29 | 2024 | 7741 | 0.360 |
Why?
|
ErbB Receptors | 12 | 2021 | 2376 | 0.360 |
Why?
|
STAT3 Transcription Factor | 6 | 2015 | 1135 | 0.360 |
Why?
|
Estrogen Antagonists | 6 | 2020 | 188 | 0.360 |
Why?
|
Aromatase Inhibitors | 4 | 2020 | 311 | 0.360 |
Why?
|
Stem Cells | 6 | 2018 | 1211 | 0.350 |
Why?
|
Risk Management | 1 | 2011 | 112 | 0.350 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 23 | 2024 | 16640 | 0.350 |
Why?
|
Mice, Nude | 26 | 2021 | 4329 | 0.340 |
Why?
|
Survival Analysis | 23 | 2020 | 9288 | 0.340 |
Why?
|
Neoadjuvant Therapy | 21 | 2023 | 5225 | 0.330 |
Why?
|
Uterine Cervical Neoplasms | 8 | 2023 | 1900 | 0.330 |
Why?
|
Anticarcinogenic Agents | 8 | 2009 | 368 | 0.320 |
Why?
|
Neoplasm Staging | 25 | 2022 | 13996 | 0.320 |
Why?
|
Neoplasms, Hormone-Dependent | 6 | 2018 | 347 | 0.320 |
Why?
|
Breast | 9 | 2022 | 1366 | 0.310 |
Why?
|
Interleukin-8 | 3 | 2016 | 527 | 0.310 |
Why?
|
Community Participation | 1 | 2009 | 54 | 0.310 |
Why?
|
Ethics, Medical | 1 | 2011 | 436 | 0.310 |
Why?
|
Consumer Health Information | 1 | 2009 | 49 | 0.310 |
Why?
|
Public Opinion | 1 | 2009 | 77 | 0.310 |
Why?
|
Middle Aged | 89 | 2020 | 90030 | 0.310 |
Why?
|
Nuclear Receptor Coactivators | 3 | 2014 | 84 | 0.310 |
Why?
|
Carcinoma, Ductal, Breast | 7 | 2015 | 1229 | 0.300 |
Why?
|
Asthenopia | 1 | 2007 | 2 | 0.300 |
Why?
|
Eye Protective Devices | 1 | 2007 | 9 | 0.300 |
Why?
|
Computer Terminals | 1 | 2007 | 12 | 0.300 |
Why?
|
Arthralgia | 2 | 2019 | 97 | 0.300 |
Why?
|
Mice, Transgenic | 25 | 2018 | 4210 | 0.300 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 3 | 2015 | 185 | 0.290 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 4 | 2021 | 690 | 0.290 |
Why?
|
Ophthalmic Solutions | 1 | 2007 | 97 | 0.290 |
Why?
|
Chemotherapy, Adjuvant | 9 | 2017 | 3993 | 0.290 |
Why?
|
Insulin-Like Growth Factor I | 7 | 2011 | 629 | 0.280 |
Why?
|
Mutation | 23 | 2021 | 15900 | 0.280 |
Why?
|
Phosphorylation | 15 | 2021 | 4939 | 0.280 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2020 | 2646 | 0.280 |
Why?
|
Adult | 74 | 2024 | 81689 | 0.280 |
Why?
|
Physician's Role | 1 | 2009 | 229 | 0.280 |
Why?
|
Disease Models, Animal | 19 | 2021 | 7343 | 0.270 |
Why?
|
Tumor Cells, Cultured | 28 | 2021 | 5757 | 0.270 |
Why?
|
Tumor Suppressor Protein p53 | 14 | 2015 | 3653 | 0.270 |
Why?
|
Research Design | 7 | 2016 | 1569 | 0.270 |
Why?
|
Neoplasm Transplantation | 16 | 2021 | 1555 | 0.270 |
Why?
|
Tears | 1 | 2007 | 165 | 0.270 |
Why?
|
Neoplasm Recurrence, Local | 15 | 2022 | 10382 | 0.260 |
Why?
|
Receptors, Androgen | 3 | 2020 | 856 | 0.260 |
Why?
|
Transcriptome | 6 | 2019 | 1954 | 0.260 |
Why?
|
Social Support | 1 | 2009 | 590 | 0.260 |
Why?
|
Breast Diseases | 2 | 2016 | 200 | 0.250 |
Why?
|
Neoplasms, Experimental | 5 | 2017 | 784 | 0.250 |
Why?
|
Cell Division | 19 | 2013 | 2651 | 0.250 |
Why?
|
Ovarian Neoplasms | 8 | 2011 | 4785 | 0.250 |
Why?
|
Molecular Targeted Therapy | 6 | 2020 | 2391 | 0.250 |
Why?
|
Nuclear Receptor Coactivator 3 | 5 | 2016 | 378 | 0.250 |
Why?
|
Repressor Proteins | 5 | 2014 | 1716 | 0.250 |
Why?
|
PTEN Phosphohydrolase | 3 | 2017 | 1012 | 0.250 |
Why?
|
Internet | 2 | 2009 | 689 | 0.250 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2024 | 1231 | 0.250 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 12 | 2 | 2018 | 31 | 0.240 |
Why?
|
Genes, BRCA1 | 4 | 2012 | 396 | 0.240 |
Why?
|
Aged | 65 | 2020 | 73127 | 0.240 |
Why?
|
Informed Consent | 4 | 2013 | 416 | 0.230 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 4 | 2023 | 529 | 0.230 |
Why?
|
Antineoplastic Agents, Phytogenic | 8 | 2005 | 894 | 0.230 |
Why?
|
Wnt1 Protein | 4 | 2018 | 100 | 0.230 |
Why?
|
Pyrophosphatases | 1 | 2024 | 49 | 0.230 |
Why?
|
RNA, Messenger | 20 | 2023 | 6368 | 0.230 |
Why?
|
Dry Eye Syndromes | 1 | 2007 | 261 | 0.230 |
Why?
|
Gene Expression Regulation | 12 | 2016 | 4118 | 0.230 |
Why?
|
Adenocarcinoma | 12 | 2024 | 7883 | 0.230 |
Why?
|
MCF-7 Cells | 7 | 2020 | 547 | 0.220 |
Why?
|
Papillomavirus Infections | 2 | 2023 | 999 | 0.220 |
Why?
|
Neurofibromin 1 | 2 | 2023 | 84 | 0.220 |
Why?
|
Keratin-6 | 2 | 2015 | 40 | 0.220 |
Why?
|
Mice, SCID | 9 | 2021 | 1826 | 0.220 |
Why?
|
Interleukin-6 | 4 | 2017 | 1042 | 0.220 |
Why?
|
DNA Repair | 4 | 2019 | 1910 | 0.220 |
Why?
|
Transcription, Genetic | 9 | 2017 | 3337 | 0.220 |
Why?
|
Treatment Outcome | 38 | 2023 | 33691 | 0.210 |
Why?
|
Progesterone | 4 | 2017 | 711 | 0.210 |
Why?
|
Ki-67 Antigen | 6 | 2014 | 675 | 0.200 |
Why?
|
Epithelial-Mesenchymal Transition | 3 | 2017 | 1002 | 0.200 |
Why?
|
Proteogenomics | 1 | 2023 | 109 | 0.200 |
Why?
|
Oncolytic Viruses | 1 | 2024 | 169 | 0.200 |
Why?
|
Genetic Research | 2 | 2013 | 66 | 0.200 |
Why?
|
Computer Simulation | 2 | 2016 | 1570 | 0.200 |
Why?
|
Emphysema | 2 | 2014 | 88 | 0.200 |
Why?
|
Janus Kinase 2 | 2 | 2018 | 754 | 0.200 |
Why?
|
Mastectomy | 7 | 2017 | 1553 | 0.200 |
Why?
|
Tumor Stem Cell Assay | 10 | 2011 | 230 | 0.200 |
Why?
|
Financing, Organized | 1 | 2021 | 21 | 0.190 |
Why?
|
Protein Array Analysis | 4 | 2018 | 501 | 0.190 |
Why?
|
Medical Oncology | 3 | 2021 | 1463 | 0.190 |
Why?
|
Pancreatectomy | 4 | 2010 | 694 | 0.190 |
Why?
|
Genetic Privacy | 2 | 2011 | 43 | 0.190 |
Why?
|
Protein Tyrosine Phosphatases | 2 | 2016 | 190 | 0.190 |
Why?
|
Heat-Shock Proteins | 6 | 2001 | 330 | 0.190 |
Why?
|
Paclitaxel | 8 | 2024 | 2101 | 0.190 |
Why?
|
Promoter Regions, Genetic | 8 | 2016 | 3210 | 0.190 |
Why?
|
Neoplasm Invasiveness | 12 | 2021 | 4043 | 0.180 |
Why?
|
S Phase | 5 | 1998 | 288 | 0.180 |
Why?
|
Minority Groups | 2 | 2020 | 328 | 0.180 |
Why?
|
Pyridines | 4 | 2024 | 1310 | 0.180 |
Why?
|
Tenascin | 2 | 2017 | 50 | 0.180 |
Why?
|
Lymphatic Metastasis | 19 | 2013 | 4956 | 0.180 |
Why?
|
Clinical Trials as Topic | 8 | 2015 | 3842 | 0.180 |
Why?
|
Health Care Surveys | 3 | 2011 | 418 | 0.180 |
Why?
|
Time Factors | 21 | 2021 | 12953 | 0.180 |
Why?
|
Cluster Analysis | 4 | 2018 | 1068 | 0.180 |
Why?
|
Cell Movement | 9 | 2021 | 2460 | 0.180 |
Why?
|
Male | 55 | 2024 | 127917 | 0.180 |
Why?
|
Carcinoma, Lobular | 3 | 2010 | 616 | 0.180 |
Why?
|
Genes, p53 | 7 | 2004 | 1140 | 0.170 |
Why?
|
Germ-Line Mutation | 2 | 2024 | 1101 | 0.170 |
Why?
|
Disclosure | 2 | 2018 | 180 | 0.170 |
Why?
|
Methylphenidate | 1 | 2020 | 91 | 0.170 |
Why?
|
Research Personnel | 1 | 2021 | 166 | 0.170 |
Why?
|
Hypothalamic Diseases | 1 | 2020 | 42 | 0.170 |
Why?
|
Phosphatidylinositol 3-Kinases | 5 | 2019 | 1708 | 0.170 |
Why?
|
DNA Methylation | 4 | 2022 | 2760 | 0.170 |
Why?
|
Disease-Free Survival | 16 | 2017 | 10258 | 0.170 |
Why?
|
Mevalonic Acid | 1 | 2019 | 32 | 0.170 |
Why?
|
Research Subjects | 2 | 2013 | 64 | 0.170 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 2 | 2016 | 65 | 0.170 |
Why?
|
GTPase-Activating Proteins | 2 | 2010 | 132 | 0.170 |
Why?
|
Safety-net Providers | 1 | 2020 | 55 | 0.170 |
Why?
|
Genome, Human | 4 | 2011 | 1885 | 0.170 |
Why?
|
Metformin | 1 | 2023 | 393 | 0.170 |
Why?
|
Aging | 4 | 2001 | 1525 | 0.170 |
Why?
|
Cholecalciferol | 1 | 2019 | 49 | 0.160 |
Why?
|
Carrier Proteins | 4 | 2014 | 2100 | 0.160 |
Why?
|
Cell Survival | 11 | 2021 | 3056 | 0.160 |
Why?
|
Parents | 2 | 2018 | 1084 | 0.160 |
Why?
|
Kaplan-Meier Estimate | 11 | 2021 | 6254 | 0.160 |
Why?
|
Wnt Proteins | 1 | 2021 | 384 | 0.160 |
Why?
|
Transfection | 15 | 2013 | 3115 | 0.160 |
Why?
|
Abdomen | 4 | 1997 | 349 | 0.160 |
Why?
|
Genes, erbB-2 | 6 | 2010 | 228 | 0.160 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 14 | 2010 | 3602 | 0.160 |
Why?
|
Consent Forms | 2 | 2011 | 26 | 0.160 |
Why?
|
Cinnamates | 1 | 2018 | 29 | 0.160 |
Why?
|
Central Nervous System Stimulants | 1 | 2020 | 195 | 0.160 |
Why?
|
Transplantation, Heterologous | 13 | 2011 | 1054 | 0.160 |
Why?
|
Thrombocytopenia | 1 | 2024 | 870 | 0.160 |
Why?
|
Pancreatic Fistula | 2 | 2010 | 102 | 0.160 |
Why?
|
Selective Estrogen Receptor Modulators | 4 | 2011 | 128 | 0.160 |
Why?
|
Cell Cycle | 10 | 2016 | 2136 | 0.160 |
Why?
|
Estrogen Receptor Modulators | 3 | 2004 | 110 | 0.160 |
Why?
|
Heterografts | 5 | 2021 | 739 | 0.150 |
Why?
|
Pleural Neoplasms | 1 | 2023 | 485 | 0.150 |
Why?
|
Mitogen-Activated Protein Kinases | 6 | 2014 | 668 | 0.150 |
Why?
|
Anemia | 1 | 2024 | 725 | 0.150 |
Why?
|
Antibodies, Monoclonal, Humanized | 10 | 2020 | 3398 | 0.150 |
Why?
|
Pancreatic Neoplasms | 6 | 2024 | 5250 | 0.150 |
Why?
|
Tissue Array Analysis | 6 | 2021 | 757 | 0.150 |
Why?
|
Gene Amplification | 3 | 2019 | 766 | 0.150 |
Why?
|
Biomarkers | 8 | 2021 | 5046 | 0.150 |
Why?
|
Exome | 2 | 2024 | 1248 | 0.150 |
Why?
|
Mesothelioma | 1 | 2023 | 558 | 0.150 |
Why?
|
Promyelocytic Leukemia Protein | 1 | 2017 | 56 | 0.150 |
Why?
|
Mice, Inbred NOD | 5 | 2021 | 897 | 0.140 |
Why?
|
Protein Kinase Inhibitors | 6 | 2024 | 4958 | 0.140 |
Why?
|
Nanocapsules | 1 | 2017 | 28 | 0.140 |
Why?
|
Nanotubes, Carbon | 1 | 2017 | 30 | 0.140 |
Why?
|
Cytochrome P-450 CYP2D6 | 1 | 2017 | 44 | 0.140 |
Why?
|
Follow-Up Studies | 13 | 2020 | 15172 | 0.140 |
Why?
|
Craniospinal Irradiation | 1 | 2018 | 132 | 0.140 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2018 | 1347 | 0.140 |
Why?
|
Mice, Inbred C57BL | 13 | 2018 | 7038 | 0.140 |
Why?
|
Bacterial Proteins | 4 | 2019 | 1081 | 0.140 |
Why?
|
Claudins | 2 | 2014 | 55 | 0.140 |
Why?
|
Up-Regulation | 5 | 2015 | 2417 | 0.140 |
Why?
|
Zinc Finger Protein GLI1 | 1 | 2017 | 114 | 0.140 |
Why?
|
Proportional Hazards Models | 14 | 2014 | 5099 | 0.140 |
Why?
|
Predictive Value of Tests | 10 | 2013 | 4944 | 0.140 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 1997 | 66 | 0.140 |
Why?
|
Receptors, Calcitriol | 1 | 2017 | 140 | 0.140 |
Why?
|
Genes, Tumor Suppressor | 3 | 2021 | 1125 | 0.140 |
Why?
|
Pancreaticoduodenectomy | 2 | 2011 | 706 | 0.140 |
Why?
|
DNA, Neoplasm | 9 | 2012 | 1957 | 0.140 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 1997 | 136 | 0.140 |
Why?
|
CELF1 Protein | 1 | 2016 | 49 | 0.140 |
Why?
|
Neoplasm Proteins | 6 | 2016 | 3343 | 0.140 |
Why?
|
Hypothyroidism | 1 | 2018 | 207 | 0.140 |
Why?
|
Dose-Response Relationship, Drug | 14 | 2021 | 5061 | 0.140 |
Why?
|
Paracrine Communication | 1 | 2017 | 127 | 0.140 |
Why?
|
Weight Loss | 2 | 2020 | 629 | 0.140 |
Why?
|
Mitogen-Activated Protein Kinase Phosphatases | 1 | 2016 | 31 | 0.140 |
Why?
|
Oncologists | 1 | 2018 | 136 | 0.140 |
Why?
|
Dual-Specificity Phosphatases | 1 | 2016 | 40 | 0.140 |
Why?
|
Alopecia | 1 | 2017 | 123 | 0.140 |
Why?
|
Postoperative Complications | 8 | 2013 | 5666 | 0.140 |
Why?
|
Trans-Activators | 6 | 2005 | 1620 | 0.140 |
Why?
|
Lung Neoplasms | 12 | 2023 | 12019 | 0.130 |
Why?
|
Amyloid beta-Peptides | 1 | 2018 | 226 | 0.130 |
Why?
|
Histone Deacetylases | 2 | 2011 | 364 | 0.130 |
Why?
|
Databases, Factual | 4 | 2019 | 2231 | 0.130 |
Why?
|
Carcinogenesis | 4 | 2015 | 1035 | 0.130 |
Why?
|
Algorithms | 5 | 2022 | 3896 | 0.130 |
Why?
|
Aged, 80 and over | 21 | 2019 | 30923 | 0.130 |
Why?
|
Transcription Factors | 8 | 2019 | 5434 | 0.130 |
Why?
|
RNA, Small Interfering | 8 | 2016 | 2197 | 0.130 |
Why?
|
Blotting, Western | 11 | 2010 | 3588 | 0.130 |
Why?
|
Interleukin-1beta | 1 | 2017 | 295 | 0.130 |
Why?
|
I-kappa B Kinase | 1 | 2017 | 248 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-jun | 6 | 2008 | 181 | 0.130 |
Why?
|
Integrins | 1 | 2017 | 272 | 0.130 |
Why?
|
Syndrome | 2 | 2011 | 1405 | 0.130 |
Why?
|
Piperazines | 2 | 2024 | 2145 | 0.130 |
Why?
|
Tumor Suppressor Proteins | 3 | 2017 | 1900 | 0.130 |
Why?
|
GTP-Binding Protein alpha Subunit, Gi2 | 1 | 2015 | 11 | 0.130 |
Why?
|
SOXC Transcription Factors | 1 | 2016 | 58 | 0.130 |
Why?
|
Receptors, Cell Surface | 2 | 2018 | 904 | 0.130 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinase Kinase | 1 | 2016 | 58 | 0.130 |
Why?
|
Cisplatin | 5 | 2017 | 2497 | 0.130 |
Why?
|
Camptothecin | 5 | 1999 | 540 | 0.130 |
Why?
|
Protons | 1 | 2018 | 481 | 0.130 |
Why?
|
Indoles | 2 | 2018 | 1026 | 0.130 |
Why?
|
Smoking | 4 | 2014 | 2548 | 0.130 |
Why?
|
Proinsulin | 1 | 2015 | 14 | 0.130 |
Why?
|
Prostatic Neoplasms | 5 | 2017 | 5860 | 0.130 |
Why?
|
Scalp | 1 | 2017 | 155 | 0.130 |
Why?
|
Hypothermia, Induced | 1 | 2017 | 177 | 0.130 |
Why?
|
Retrospective Studies | 26 | 2023 | 39736 | 0.130 |
Why?
|
Antibodies, Monoclonal | 5 | 2010 | 4463 | 0.130 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2018 | 1564 | 0.120 |
Why?
|
Calmodulin | 1 | 2016 | 260 | 0.120 |
Why?
|
Biopsy, Large-Core Needle | 1 | 2016 | 139 | 0.120 |
Why?
|
Methotrexate | 1 | 2018 | 1025 | 0.120 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 2 | 2013 | 95 | 0.120 |
Why?
|
Osteopontin | 2 | 2014 | 143 | 0.120 |
Why?
|
Societies, Medical | 1 | 2021 | 1318 | 0.120 |
Why?
|
E2F1 Transcription Factor | 1 | 2016 | 199 | 0.120 |
Why?
|
Genes, BRCA2 | 2 | 2011 | 321 | 0.120 |
Why?
|
Genes, Regulator | 2 | 2006 | 81 | 0.120 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2016 | 262 | 0.120 |
Why?
|
Triazines | 3 | 2010 | 122 | 0.120 |
Why?
|
Surveys and Questionnaires | 7 | 2024 | 5906 | 0.120 |
Why?
|
GATA2 Transcription Factor | 1 | 2014 | 67 | 0.120 |
Why?
|
Texas | 10 | 2024 | 6430 | 0.120 |
Why?
|
Lymphocytes | 1 | 2019 | 1272 | 0.120 |
Why?
|
Genes, myc | 2 | 2011 | 372 | 0.120 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1017 | 0.120 |
Why?
|
Tumor Microenvironment | 5 | 2024 | 3030 | 0.120 |
Why?
|
Securin | 1 | 2014 | 12 | 0.120 |
Why?
|
MAP Kinase Kinase Kinase 3 | 1 | 2014 | 22 | 0.120 |
Why?
|
Bone and Bones | 1 | 2017 | 606 | 0.120 |
Why?
|
Medulloblastoma | 2 | 2018 | 572 | 0.120 |
Why?
|
Stromal Cells | 2 | 2015 | 826 | 0.110 |
Why?
|
Neuroepithelial Cells | 1 | 2013 | 12 | 0.110 |
Why?
|
Young Adult | 9 | 2024 | 22134 | 0.110 |
Why?
|
Veratrum Alkaloids | 2 | 2017 | 35 | 0.110 |
Why?
|
Serine Endopeptidases | 1 | 2015 | 273 | 0.110 |
Why?
|
Nuclear Receptor Co-Repressor 2 | 2 | 2012 | 45 | 0.110 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 625 | 0.110 |
Why?
|
Healthcare Disparities | 1 | 2020 | 654 | 0.110 |
Why?
|
Semaphorins | 1 | 2013 | 37 | 0.110 |
Why?
|
Lung Diseases, Obstructive | 1 | 1993 | 48 | 0.110 |
Why?
|
Research Report | 1 | 2014 | 136 | 0.110 |
Why?
|
Brain Neoplasms | 3 | 2020 | 4955 | 0.110 |
Why?
|
Integrin beta1 | 2 | 2011 | 128 | 0.110 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2015 | 217 | 0.110 |
Why?
|
Mice, Knockout | 10 | 2015 | 5694 | 0.110 |
Why?
|
Mitotic Index | 2 | 1999 | 162 | 0.110 |
Why?
|
Adipose Tissue | 2 | 2015 | 717 | 0.110 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2016 | 622 | 0.110 |
Why?
|
Immunohistochemistry | 14 | 2015 | 7632 | 0.110 |
Why?
|
Thiazolidinediones | 1 | 2014 | 147 | 0.110 |
Why?
|
GTP Phosphohydrolases | 1 | 2015 | 335 | 0.110 |
Why?
|
Anthracyclines | 2 | 2017 | 339 | 0.110 |
Why?
|
Down-Regulation | 6 | 2016 | 2089 | 0.110 |
Why?
|
Adolescent | 14 | 2024 | 32647 | 0.110 |
Why?
|
Somatomedins | 3 | 1999 | 74 | 0.110 |
Why?
|
Comprehension | 1 | 2013 | 103 | 0.110 |
Why?
|
Insulin Resistance | 2 | 2016 | 728 | 0.110 |
Why?
|
Fibroblasts | 2 | 2016 | 1628 | 0.110 |
Why?
|
PPAR gamma | 1 | 2014 | 223 | 0.110 |
Why?
|
Morbidity | 2 | 2000 | 399 | 0.110 |
Why?
|
Calcinosis | 1 | 2016 | 425 | 0.100 |
Why?
|
Carnitine Acyltransferases | 1 | 2012 | 6 | 0.100 |
Why?
|
Cancer Survivors | 1 | 2020 | 744 | 0.100 |
Why?
|
Mental Recall | 1 | 2013 | 171 | 0.100 |
Why?
|
Proteome | 2 | 2021 | 571 | 0.100 |
Why?
|
Cell Nucleus | 3 | 2020 | 1711 | 0.100 |
Why?
|
Communication | 1 | 2018 | 835 | 0.100 |
Why?
|
Hyperglycemia | 1 | 2015 | 337 | 0.100 |
Why?
|
Risk Factors | 16 | 2019 | 17824 | 0.100 |
Why?
|
Insulin Receptor Substrate Proteins | 3 | 2009 | 144 | 0.100 |
Why?
|
Receptors, Retinoic Acid | 3 | 2002 | 369 | 0.100 |
Why?
|
Nuclear Proteins | 6 | 2014 | 3437 | 0.100 |
Why?
|
Growth Inhibitors | 2 | 2003 | 163 | 0.100 |
Why?
|
Radiology Information Systems | 1 | 2013 | 119 | 0.100 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2017 | 1276 | 0.100 |
Why?
|
Reproducibility of Results | 6 | 2020 | 6182 | 0.100 |
Why?
|
LIM Domain Proteins | 1 | 2012 | 103 | 0.100 |
Why?
|
Cognition | 1 | 2018 | 968 | 0.100 |
Why?
|
Receptor, IGF Type 1 | 2 | 2011 | 351 | 0.100 |
Why?
|
Green Fluorescent Proteins | 2 | 2014 | 692 | 0.100 |
Why?
|
Doxycycline | 2 | 2014 | 179 | 0.100 |
Why?
|
DNA Damage | 2 | 2019 | 1981 | 0.100 |
Why?
|
Disease Progression | 7 | 2021 | 6840 | 0.100 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2013 | 235 | 0.100 |
Why?
|
Polymorphism, Genetic | 1 | 2017 | 1557 | 0.100 |
Why?
|
Cross-Over Studies | 2 | 2012 | 452 | 0.100 |
Why?
|
Ubiquitin-Activating Enzymes | 1 | 2011 | 53 | 0.100 |
Why?
|
Transgenes | 5 | 2018 | 574 | 0.100 |
Why?
|
Guanine Nucleotide Dissociation Inhibitors | 1 | 2011 | 15 | 0.100 |
Why?
|
Sesquiterpenes | 3 | 2000 | 70 | 0.100 |
Why?
|
Research | 1 | 2014 | 426 | 0.100 |
Why?
|
Child | 14 | 2024 | 30466 | 0.100 |
Why?
|
Cell Adhesion | 6 | 2017 | 1008 | 0.100 |
Why?
|
Decision Making | 3 | 2018 | 1249 | 0.090 |
Why?
|
Neurogenesis | 1 | 2013 | 241 | 0.090 |
Why?
|
Multivariate Analysis | 7 | 2012 | 4318 | 0.090 |
Why?
|
Learning Curve | 1 | 2011 | 78 | 0.090 |
Why?
|
Muscular Diseases | 1 | 2012 | 161 | 0.090 |
Why?
|
BRCA1 Protein | 2 | 2012 | 525 | 0.090 |
Why?
|
Oncogenes | 2 | 2013 | 700 | 0.090 |
Why?
|
Costs and Cost Analysis | 2 | 2011 | 310 | 0.090 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2014 | 460 | 0.090 |
Why?
|
Pyrazoles | 2 | 2010 | 1539 | 0.090 |
Why?
|
Genes, Dominant | 3 | 2006 | 356 | 0.090 |
Why?
|
Gene Expression Regulation, Developmental | 3 | 2014 | 1503 | 0.090 |
Why?
|
Analysis of Variance | 8 | 2009 | 2316 | 0.090 |
Why?
|
Heterozygote | 2 | 2011 | 1055 | 0.090 |
Why?
|
N-Acetylneuraminic Acid | 1 | 1990 | 34 | 0.090 |
Why?
|
Genotype | 3 | 2017 | 4249 | 0.090 |
Why?
|
Fluorouracil | 5 | 2014 | 1989 | 0.090 |
Why?
|
Ultrasonography, Mammary | 1 | 2013 | 387 | 0.090 |
Why?
|
Prospective Studies | 10 | 2023 | 13378 | 0.090 |
Why?
|
Antigens, Viral, Tumor | 1 | 2010 | 72 | 0.090 |
Why?
|
Alzheimer Disease | 1 | 2018 | 817 | 0.090 |
Why?
|
Polyomavirus | 1 | 2010 | 37 | 0.090 |
Why?
|
Biometry | 1 | 1992 | 250 | 0.090 |
Why?
|
Nanoshells | 1 | 2010 | 43 | 0.090 |
Why?
|
Single-Blind Method | 1 | 2011 | 415 | 0.090 |
Why?
|
Small Molecule Libraries | 1 | 2012 | 195 | 0.090 |
Why?
|
Gene Rearrangement | 1 | 2014 | 812 | 0.090 |
Why?
|
Th17 Cells | 1 | 2012 | 163 | 0.090 |
Why?
|
Oncogene Proteins | 2 | 2010 | 367 | 0.090 |
Why?
|
Retinoid X Receptors | 3 | 2005 | 86 | 0.090 |
Why?
|
Risk | 3 | 2011 | 1937 | 0.090 |
Why?
|
Lymph Nodes | 4 | 1997 | 3070 | 0.090 |
Why?
|
Sirolimus | 1 | 2014 | 831 | 0.090 |
Why?
|
Lymphoma, Large-Cell, Immunoblastic | 1 | 2009 | 17 | 0.090 |
Why?
|
Doxorubicin | 5 | 2015 | 3142 | 0.090 |
Why?
|
Metabolome | 1 | 2013 | 355 | 0.090 |
Why?
|
Neoplasms, Plasma Cell | 1 | 2009 | 23 | 0.090 |
Why?
|
Obesity | 2 | 2020 | 2901 | 0.090 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2015 | 637 | 0.090 |
Why?
|
Interleukin-17 | 1 | 2012 | 256 | 0.090 |
Why?
|
Immunoblotting | 6 | 2011 | 892 | 0.090 |
Why?
|
Calcium | 1 | 2016 | 1540 | 0.090 |
Why?
|
Patient Selection | 2 | 2015 | 2026 | 0.080 |
Why?
|
Macrophages | 2 | 2015 | 1338 | 0.080 |
Why?
|
Hot Flashes | 1 | 2009 | 35 | 0.080 |
Why?
|
Immunoenzyme Techniques | 5 | 2010 | 1184 | 0.080 |
Why?
|
Thoracic Surgery | 1 | 1993 | 282 | 0.080 |
Why?
|
Sertraline | 1 | 2009 | 42 | 0.080 |
Why?
|
Genes, ras | 3 | 2015 | 679 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 4 | 2021 | 1542 | 0.080 |
Why?
|
Cell Differentiation | 5 | 2018 | 4104 | 0.080 |
Why?
|
Medicine | 1 | 2011 | 136 | 0.080 |
Why?
|
DNA-Binding Proteins | 5 | 2019 | 5000 | 0.080 |
Why?
|
Survival Rate | 13 | 2010 | 12508 | 0.080 |
Why?
|
Private Sector | 1 | 2009 | 30 | 0.080 |
Why?
|
Cytokines | 3 | 2013 | 2810 | 0.080 |
Why?
|
Matrix Attachment Region Binding Proteins | 1 | 2009 | 25 | 0.080 |
Why?
|
Nuclear Matrix-Associated Proteins | 1 | 2009 | 35 | 0.080 |
Why?
|
Cadherins | 1 | 2012 | 656 | 0.080 |
Why?
|
Premenopause | 2 | 2001 | 138 | 0.080 |
Why?
|
Microdissection | 1 | 2009 | 84 | 0.080 |
Why?
|
Papillomaviridae | 2 | 2023 | 636 | 0.080 |
Why?
|
Medroxyprogesterone | 1 | 1988 | 13 | 0.080 |
Why?
|
Gold | 1 | 2010 | 267 | 0.080 |
Why?
|
Marketing of Health Services | 1 | 2009 | 33 | 0.080 |
Why?
|
Access to Information | 1 | 2009 | 52 | 0.080 |
Why?
|
Child, Preschool | 9 | 2024 | 16987 | 0.080 |
Why?
|
Mice, Inbred BALB C | 8 | 2010 | 2452 | 0.080 |
Why?
|
Colorectal Neoplasms | 3 | 2020 | 3699 | 0.080 |
Why?
|
DNA | 2 | 2016 | 3046 | 0.080 |
Why?
|
Phosphoproteins | 3 | 1999 | 1136 | 0.080 |
Why?
|
Mastectomy, Segmental | 2 | 1994 | 1049 | 0.080 |
Why?
|
Shock, Hemorrhagic | 1 | 2009 | 76 | 0.080 |
Why?
|
Membrane Proteins | 4 | 2013 | 2926 | 0.080 |
Why?
|
Plasmids | 3 | 2011 | 936 | 0.080 |
Why?
|
Peptide Fragments | 4 | 2008 | 1305 | 0.080 |
Why?
|
Autistic Disorder | 1 | 2011 | 352 | 0.080 |
Why?
|
Decision Making, Computer-Assisted | 2 | 2002 | 33 | 0.080 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2015 | 1570 | 0.080 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 343 | 0.080 |
Why?
|
DNA, Complementary | 2 | 2000 | 936 | 0.080 |
Why?
|
Tissue Adhesives | 1 | 2008 | 47 | 0.080 |
Why?
|
Head and Neck Neoplasms | 1 | 2023 | 4139 | 0.070 |
Why?
|
Fluorophotometry | 1 | 2007 | 32 | 0.070 |
Why?
|
Environment, Controlled | 1 | 2007 | 22 | 0.070 |
Why?
|
Nicotinic Acids | 1 | 2007 | 35 | 0.070 |
Why?
|
Drainage | 1 | 2010 | 462 | 0.070 |
Why?
|
Lasers | 1 | 2009 | 235 | 0.070 |
Why?
|
Carcinoma | 4 | 1992 | 2607 | 0.070 |
Why?
|
Transcriptional Activation | 5 | 2016 | 1107 | 0.070 |
Why?
|
Osteosarcoma | 1 | 2015 | 948 | 0.070 |
Why?
|
Flow Cytometry | 7 | 2014 | 3037 | 0.070 |
Why?
|
Hedgehog Proteins | 2 | 2008 | 440 | 0.070 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 3 | 1997 | 63 | 0.070 |
Why?
|
Physicians | 2 | 2018 | 851 | 0.070 |
Why?
|
Fixatives | 1 | 2007 | 30 | 0.070 |
Why?
|
Gene Expression Regulation, Bacterial | 2 | 2006 | 205 | 0.070 |
Why?
|
Myelopoiesis | 1 | 2007 | 34 | 0.070 |
Why?
|
Mesoderm | 1 | 2009 | 392 | 0.070 |
Why?
|
Drug Delivery Systems | 2 | 2009 | 661 | 0.070 |
Why?
|
Radiation Tolerance | 1 | 2010 | 637 | 0.070 |
Why?
|
Education, Medical, Graduate | 1 | 2013 | 700 | 0.070 |
Why?
|
Bacterial Capsules | 2 | 2004 | 41 | 0.070 |
Why?
|
Comparative Genomic Hybridization | 1 | 2009 | 691 | 0.070 |
Why?
|
Incidence | 8 | 2009 | 5806 | 0.070 |
Why?
|
RNA, Neoplasm | 5 | 2009 | 806 | 0.070 |
Why?
|
Fibrocystic Breast Disease | 1 | 2007 | 45 | 0.070 |
Why?
|
Smoothened Receptor | 3 | 2015 | 53 | 0.070 |
Why?
|
Bone Neoplasms | 3 | 2017 | 2663 | 0.070 |
Why?
|
Shock | 1 | 2008 | 93 | 0.070 |
Why?
|
Registries | 3 | 1999 | 2205 | 0.070 |
Why?
|
Tissue Fixation | 1 | 2007 | 136 | 0.070 |
Why?
|
Formaldehyde | 1 | 2007 | 115 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2011 | 840 | 0.070 |
Why?
|
Fatty Acids | 3 | 2016 | 434 | 0.070 |
Why?
|
Paraffin Embedding | 1 | 2007 | 221 | 0.070 |
Why?
|
Patient Acceptance of Health Care | 2 | 2023 | 599 | 0.070 |
Why?
|
Genetic Heterogeneity | 2 | 2006 | 326 | 0.070 |
Why?
|
Receptors, Interleukin | 1 | 2006 | 99 | 0.070 |
Why?
|
MicroRNAs | 3 | 2015 | 2887 | 0.070 |
Why?
|
Linear Models | 3 | 2013 | 1095 | 0.070 |
Why?
|
Brain Mapping | 1 | 2010 | 624 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 2 | 1992 | 5585 | 0.070 |
Why?
|
Nucleic Acid Hybridization | 3 | 2005 | 631 | 0.070 |
Why?
|
Counseling | 1 | 2009 | 381 | 0.070 |
Why?
|
Cathepsin D | 2 | 1997 | 33 | 0.070 |
Why?
|
Virus Latency | 2 | 2015 | 79 | 0.070 |
Why?
|
Enterococcus faecalis | 1 | 2006 | 58 | 0.070 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 2 | 1997 | 156 | 0.070 |
Why?
|
Phenotype | 8 | 2014 | 6485 | 0.070 |
Why?
|
Hyperthermia, Induced | 1 | 2010 | 511 | 0.070 |
Why?
|
Drug Screening Assays, Antitumor | 7 | 2000 | 562 | 0.070 |
Why?
|
Nerve Tissue Proteins | 1 | 2013 | 1581 | 0.070 |
Why?
|
Myeloid Cells | 1 | 2007 | 271 | 0.070 |
Why?
|
Mammaplasty | 1 | 2013 | 714 | 0.070 |
Why?
|
Age Factors | 6 | 2013 | 5449 | 0.060 |
Why?
|
Enzyme Activation | 4 | 2011 | 1801 | 0.060 |
Why?
|
Deoxycytidine | 3 | 2014 | 1390 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-fos | 1 | 2005 | 133 | 0.060 |
Why?
|
Sp1 Transcription Factor | 2 | 2004 | 193 | 0.060 |
Why?
|
In Vitro Techniques | 5 | 2021 | 1690 | 0.060 |
Why?
|
Genetic Markers | 2 | 2005 | 1075 | 0.060 |
Why?
|
DNA Replication | 3 | 2019 | 771 | 0.060 |
Why?
|
Loss of Heterozygosity | 2 | 2014 | 622 | 0.060 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 2895 | 0.060 |
Why?
|
Case-Control Studies | 5 | 2017 | 6204 | 0.060 |
Why?
|
Lung | 3 | 2014 | 3288 | 0.060 |
Why?
|
Wounds and Injuries | 1 | 2009 | 441 | 0.060 |
Why?
|
Raloxifene Hydrochloride | 1 | 2004 | 46 | 0.060 |
Why?
|
Florida | 4 | 1992 | 116 | 0.060 |
Why?
|
Gambia | 1 | 2024 | 28 | 0.060 |
Why?
|
Biological Specimen Banks | 1 | 2005 | 74 | 0.060 |
Why?
|
Cell Cycle Proteins | 4 | 2014 | 2116 | 0.060 |
Why?
|
Drug Resistance | 6 | 1998 | 609 | 0.060 |
Why?
|
Pediatrics | 1 | 2014 | 1185 | 0.060 |
Why?
|
Triazoles | 3 | 2014 | 628 | 0.060 |
Why?
|
Cells, Cultured | 5 | 2018 | 5658 | 0.060 |
Why?
|
src-Family Kinases | 2 | 2011 | 488 | 0.060 |
Why?
|
Smartphone | 1 | 2024 | 48 | 0.060 |
Why?
|
DNA Probes | 1 | 2004 | 245 | 0.060 |
Why?
|
Hyperplasia | 4 | 2015 | 557 | 0.060 |
Why?
|
Patient Education as Topic | 1 | 2009 | 744 | 0.060 |
Why?
|
Diet, High-Fat | 2 | 2016 | 247 | 0.060 |
Why?
|
Phenylurea Compounds | 2 | 2015 | 599 | 0.060 |
Why?
|
Early Detection of Cancer | 2 | 2023 | 1338 | 0.060 |
Why?
|
Cohort Studies | 5 | 2008 | 9464 | 0.060 |
Why?
|
Fluorescent Antibody Technique | 4 | 2010 | 1119 | 0.060 |
Why?
|
Cytological Techniques | 2 | 1995 | 69 | 0.060 |
Why?
|
Membrane Glycoproteins | 2 | 2003 | 1094 | 0.060 |
Why?
|
Mass Screening | 2 | 2023 | 1545 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 5 | 2024 | 5773 | 0.060 |
Why?
|
Plasma | 2 | 2016 | 146 | 0.060 |
Why?
|
Epilepsy | 1 | 2011 | 947 | 0.060 |
Why?
|
Probability | 4 | 2002 | 883 | 0.060 |
Why?
|
Polymerase Chain Reaction | 8 | 2009 | 3468 | 0.060 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2022 | 770 | 0.060 |
Why?
|
Clinical Competence | 1 | 2011 | 1323 | 0.060 |
Why?
|
Sample Size | 1 | 2004 | 213 | 0.050 |
Why?
|
Menopause | 3 | 2005 | 159 | 0.050 |
Why?
|
Obstetric Labor Complications | 1 | 2024 | 99 | 0.050 |
Why?
|
Barrett Esophagus | 1 | 2009 | 545 | 0.050 |
Why?
|
Topoisomerase I Inhibitors | 2 | 1994 | 73 | 0.050 |
Why?
|
Risk Assessment | 4 | 2011 | 6752 | 0.050 |
Why?
|
Antigens, Surface | 2 | 2015 | 303 | 0.050 |
Why?
|
NFI Transcription Factors | 1 | 2023 | 78 | 0.050 |
Why?
|
Contrast Media | 1 | 2010 | 1498 | 0.050 |
Why?
|
Neoplasm, Residual | 1 | 2009 | 1742 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2020 | 686 | 0.050 |
Why?
|
Bacillus anthracis | 1 | 2003 | 45 | 0.050 |
Why?
|
Cyclin D1 | 3 | 2011 | 589 | 0.050 |
Why?
|
Coculture Techniques | 2 | 2015 | 627 | 0.050 |
Why?
|
Mobile Applications | 1 | 2024 | 108 | 0.050 |
Why?
|
Genes, Neoplasm | 3 | 2011 | 314 | 0.050 |
Why?
|
Neutrophils | 1 | 2007 | 834 | 0.050 |
Why?
|
Membrane Transport Proteins | 2 | 2019 | 246 | 0.050 |
Why?
|
Vaginal Smears | 1 | 2023 | 166 | 0.050 |
Why?
|
Mastectomy, Radical | 3 | 2000 | 40 | 0.050 |
Why?
|
Endometrial Neoplasms | 1 | 1992 | 1388 | 0.050 |
Why?
|
Drug Administration Schedule | 6 | 2013 | 3523 | 0.050 |
Why?
|
Albumins | 1 | 2024 | 263 | 0.050 |
Why?
|
Models, Biological | 5 | 2014 | 3187 | 0.050 |
Why?
|
Tissue Distribution | 3 | 2018 | 927 | 0.050 |
Why?
|
Germ Cells | 1 | 2024 | 329 | 0.050 |
Why?
|
Muscle, Skeletal | 3 | 2016 | 1287 | 0.050 |
Why?
|
Interferons | 1 | 2023 | 299 | 0.050 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2022 | 7259 | 0.050 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2021 | 622 | 0.050 |
Why?
|
Oxides | 1 | 2003 | 212 | 0.050 |
Why?
|
Laparotomy | 2 | 2008 | 234 | 0.050 |
Why?
|
Fracture Fixation, Internal | 1 | 2002 | 97 | 0.050 |
Why?
|
Confidentiality | 2 | 2013 | 118 | 0.050 |
Why?
|
Arsenicals | 1 | 2003 | 205 | 0.050 |
Why?
|
Self Care | 1 | 2023 | 247 | 0.050 |
Why?
|
Cystoscopy | 1 | 2022 | 92 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2017 | 4646 | 0.050 |
Why?
|
Gene Silencing | 3 | 2011 | 827 | 0.050 |
Why?
|
Hip Fractures | 1 | 2002 | 87 | 0.050 |
Why?
|
Mutagenesis | 2 | 2019 | 519 | 0.050 |
Why?
|
Prenatal Care | 1 | 2024 | 349 | 0.050 |
Why?
|
Infant | 6 | 2024 | 13946 | 0.050 |
Why?
|
Protein Isoforms | 3 | 2011 | 847 | 0.050 |
Why?
|
Homeodomain Proteins | 1 | 2006 | 1120 | 0.050 |
Why?
|
Colony-Forming Units Assay | 2 | 2014 | 253 | 0.050 |
Why?
|
Amino Acids | 2 | 2016 | 781 | 0.050 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2019 | 2308 | 0.050 |
Why?
|
Gene Knockdown Techniques | 2 | 2014 | 1077 | 0.050 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 383 | 0.050 |
Why?
|
Pregnancy | 4 | 2024 | 8107 | 0.050 |
Why?
|
Drug Synergism | 4 | 2016 | 1359 | 0.050 |
Why?
|
United States | 9 | 2021 | 15776 | 0.050 |
Why?
|
Regression Analysis | 5 | 2013 | 1568 | 0.050 |
Why?
|
Dihydrotestosterone | 1 | 2020 | 94 | 0.050 |
Why?
|
Rural Population | 2 | 2000 | 291 | 0.040 |
Why?
|
RNA Interference | 2 | 2017 | 1385 | 0.040 |
Why?
|
Lung Diseases | 2 | 1996 | 751 | 0.040 |
Why?
|
Hyaluronan Receptors | 2 | 2013 | 247 | 0.040 |
Why?
|
Caspases | 1 | 2003 | 677 | 0.040 |
Why?
|
Spirometry | 2 | 1997 | 153 | 0.040 |
Why?
|
Infusions, Intravenous | 5 | 2005 | 1434 | 0.040 |
Why?
|
Antibodies, Protozoan | 1 | 2000 | 86 | 0.040 |
Why?
|
Oxidative Stress | 2 | 2010 | 1145 | 0.040 |
Why?
|
Muscle Proteins | 1 | 2003 | 542 | 0.040 |
Why?
|
Uterus | 1 | 2005 | 798 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 2 | 2010 | 2388 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 2 | 2022 | 7892 | 0.040 |
Why?
|
Hepatitis Antibodies | 1 | 1999 | 11 | 0.040 |
Why?
|
Knowledge Bases | 1 | 2019 | 42 | 0.040 |
Why?
|
Cryptosporidium parvum | 1 | 2000 | 62 | 0.040 |
Why?
|
Cholecystectomy, Laparoscopic | 1 | 2000 | 75 | 0.040 |
Why?
|
Cryptosporidiosis | 1 | 2000 | 90 | 0.040 |
Why?
|
Combined Modality Therapy | 5 | 2014 | 9040 | 0.040 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2001 | 349 | 0.040 |
Why?
|
Hepatitis A | 1 | 1999 | 36 | 0.040 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2009 | 1737 | 0.040 |
Why?
|
Co-Repressor Proteins | 1 | 2020 | 120 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2014 | 2073 | 0.040 |
Why?
|
Protein Biosynthesis | 2 | 2016 | 1028 | 0.040 |
Why?
|
Hysterectomy | 2 | 1995 | 651 | 0.040 |
Why?
|
Proteins | 1 | 2008 | 2043 | 0.040 |
Why?
|
Ubiquitin | 1 | 2021 | 331 | 0.040 |
Why?
|
Sulfonamides | 1 | 2009 | 1933 | 0.040 |
Why?
|
ROC Curve | 2 | 2015 | 1248 | 0.040 |
Why?
|
In Situ Hybridization | 2 | 2005 | 1039 | 0.040 |
Why?
|
Open Reading Frames | 2 | 2014 | 276 | 0.040 |
Why?
|
Chi-Square Distribution | 3 | 2005 | 1309 | 0.040 |
Why?
|
Amino Acid Motifs | 1 | 2020 | 399 | 0.040 |
Why?
|
Medically Uninsured | 1 | 2020 | 105 | 0.040 |
Why?
|
Logistic Models | 3 | 2010 | 3438 | 0.040 |
Why?
|
Molecular Probe Techniques | 1 | 1999 | 46 | 0.040 |
Why?
|
Pregnancy Complications | 1 | 2024 | 559 | 0.040 |
Why?
|
DNA Topoisomerases, Type II | 1 | 1999 | 125 | 0.040 |
Why?
|
DNA Primers | 4 | 2007 | 1494 | 0.040 |
Why?
|
Carcinogens | 3 | 2008 | 391 | 0.040 |
Why?
|
Rats | 5 | 2009 | 6499 | 0.040 |
Why?
|
CD24 Antigen | 2 | 2009 | 88 | 0.040 |
Why?
|
Benzofurans | 1 | 1999 | 40 | 0.040 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 1999 | 189 | 0.040 |
Why?
|
Cell Separation | 2 | 2014 | 608 | 0.040 |
Why?
|
Folic Acid Antagonists | 1 | 1999 | 48 | 0.040 |
Why?
|
Tacrolimus | 1 | 2000 | 345 | 0.040 |
Why?
|
Candidiasis, Oral | 1 | 1998 | 9 | 0.040 |
Why?
|
Pimozide | 1 | 2018 | 8 | 0.040 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 2 | 2014 | 210 | 0.040 |
Why?
|
CTLA-4 Antigen | 1 | 2023 | 678 | 0.040 |
Why?
|
Anthropometry | 1 | 1999 | 264 | 0.040 |
Why?
|
Glucose | 2 | 2016 | 1211 | 0.040 |
Why?
|
Glutamates | 1 | 1999 | 132 | 0.040 |
Why?
|
Sensitivity and Specificity | 5 | 2010 | 5153 | 0.040 |
Why?
|
G2 Phase | 2 | 2003 | 218 | 0.040 |
Why?
|
Kidney Neoplasms | 2 | 2010 | 3107 | 0.040 |
Why?
|
Hyperprolactinemia | 1 | 2018 | 20 | 0.040 |
Why?
|
Phthalimides | 1 | 1998 | 5 | 0.040 |
Why?
|
Guanine | 1 | 1999 | 157 | 0.040 |
Why?
|
Wnt Signaling Pathway | 1 | 2021 | 445 | 0.040 |
Why?
|
Oropharynx | 1 | 1998 | 80 | 0.040 |
Why?
|
Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 275 | 0.040 |
Why?
|
Rats, Inbred WF | 3 | 2002 | 28 | 0.040 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2001 | 693 | 0.040 |
Why?
|
HSP70 Heat-Shock Proteins | 2 | 1996 | 163 | 0.040 |
Why?
|
Methylnitrosourea | 3 | 2002 | 50 | 0.040 |
Why?
|
Solubility | 1 | 2018 | 243 | 0.040 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 1999 | 287 | 0.040 |
Why?
|
Fluconazole | 1 | 1998 | 107 | 0.040 |
Why?
|
Mammals | 1 | 2019 | 367 | 0.040 |
Why?
|
Chorioallantoic Membrane | 1 | 2017 | 25 | 0.040 |
Why?
|
Tretinoin | 1 | 2000 | 618 | 0.040 |
Why?
|
Photoreceptor Cells | 1 | 1998 | 94 | 0.040 |
Why?
|
Plaque, Amyloid | 1 | 2018 | 63 | 0.040 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 3 | 2005 | 303 | 0.040 |
Why?
|
Risperidone | 1 | 2018 | 62 | 0.040 |
Why?
|
Chromosomal Instability | 1 | 2019 | 229 | 0.040 |
Why?
|
Professional-Family Relations | 1 | 2018 | 131 | 0.040 |
Why?
|
Pharmacogenomic Variants | 1 | 2017 | 29 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 499 | 0.040 |
Why?
|
Socioeconomic Factors | 2 | 2020 | 1255 | 0.040 |
Why?
|
NIH 3T3 Cells | 2 | 2010 | 254 | 0.040 |
Why?
|
Radiography | 1 | 2022 | 1984 | 0.040 |
Why?
|
Chick Embryo | 1 | 2017 | 219 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2018 | 188 | 0.040 |
Why?
|
Pilot Projects | 3 | 1999 | 2843 | 0.040 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 1998 | 180 | 0.040 |
Why?
|
Nitriles | 2 | 2013 | 938 | 0.040 |
Why?
|
Retinal Degeneration | 1 | 1998 | 97 | 0.040 |
Why?
|
Vidarabine | 1 | 2022 | 1383 | 0.040 |
Why?
|
Flutamide | 1 | 1997 | 44 | 0.040 |
Why?
|
Early Termination of Clinical Trials | 1 | 2017 | 84 | 0.040 |
Why?
|
Liver | 3 | 2016 | 3069 | 0.040 |
Why?
|
HEK293 Cells | 1 | 2021 | 1461 | 0.040 |
Why?
|
Genes, cdc | 1 | 1997 | 84 | 0.040 |
Why?
|
Hydroxyurea | 1 | 1998 | 224 | 0.040 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2024 | 1837 | 0.030 |
Why?
|
Androstadienes | 1 | 2017 | 172 | 0.030 |
Why?
|
Biopsy | 3 | 2009 | 3384 | 0.030 |
Why?
|
Cytosol | 1 | 1997 | 267 | 0.030 |
Why?
|
Length of Stay | 2 | 2011 | 2001 | 0.030 |
Why?
|
Neoplasms, Second Primary | 1 | 2005 | 1387 | 0.030 |
Why?
|
Cross-Sectional Studies | 2 | 2024 | 4470 | 0.030 |
Why?
|
Congenital Abnormalities | 1 | 1999 | 280 | 0.030 |
Why?
|
Cyclooxygenase Inhibitors | 2 | 2009 | 177 | 0.030 |
Why?
|
Bridged-Ring Compounds | 1 | 2017 | 190 | 0.030 |
Why?
|
Patients | 1 | 2018 | 246 | 0.030 |
Why?
|
Temporomandibular Joint Dysfunction Syndrome | 1 | 1996 | 3 | 0.030 |
Why?
|
Genes, Reporter | 2 | 2014 | 816 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2020 | 681 | 0.030 |
Why?
|
Malocclusion, Angle Class II | 1 | 1996 | 3 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2014 | 537 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2003 | 1942 | 0.030 |
Why?
|
Effect Modifier, Epidemiologic | 1 | 1996 | 20 | 0.030 |
Why?
|
Genetic Therapy | 1 | 2024 | 1713 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2014 | 1469 | 0.030 |
Why?
|
Molecular Sequence Data | 6 | 2004 | 6674 | 0.030 |
Why?
|
Virus Activation | 1 | 1998 | 236 | 0.030 |
Why?
|
Breast Neoplasms, Male | 2 | 2011 | 232 | 0.030 |
Why?
|
MAP Kinase Signaling System | 2 | 2011 | 884 | 0.030 |
Why?
|
Cytarabine | 1 | 2022 | 2013 | 0.030 |
Why?
|
Receptor, Insulin | 2 | 2010 | 110 | 0.030 |
Why?
|
B7-H1 Antigen | 1 | 2023 | 1081 | 0.030 |
Why?
|
Genomic Instability | 1 | 2019 | 520 | 0.030 |
Why?
|
Alleles | 2 | 2017 | 2590 | 0.030 |
Why?
|
ras Proteins | 1 | 2020 | 804 | 0.030 |
Why?
|
Chromosome Aberrations | 2 | 2009 | 2031 | 0.030 |
Why?
|
Ovariectomy | 2 | 2008 | 369 | 0.030 |
Why?
|
Lysosomes | 1 | 2018 | 345 | 0.030 |
Why?
|
Hospital Costs | 1 | 1997 | 242 | 0.030 |
Why?
|
Mitosis | 2 | 2011 | 680 | 0.030 |
Why?
|
Tumor Virus Infections | 1 | 1997 | 247 | 0.030 |
Why?
|
Cyclins | 1 | 1997 | 467 | 0.030 |
Why?
|
Vitamin D | 1 | 2017 | 261 | 0.030 |
Why?
|
Postmenopause | 1 | 1997 | 377 | 0.030 |
Why?
|
Epigenesis, Genetic | 1 | 2022 | 1440 | 0.030 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 1997 | 376 | 0.030 |
Why?
|
Primary Prevention | 1 | 2017 | 233 | 0.030 |
Why?
|
Receptors, Calcitonin | 1 | 1995 | 28 | 0.030 |
Why?
|
Dietary Supplements | 1 | 2019 | 562 | 0.030 |
Why?
|
Bias | 1 | 1996 | 214 | 0.030 |
Why?
|
Drosophila | 2 | 2015 | 909 | 0.030 |
Why?
|
Statistics, Nonparametric | 2 | 2013 | 982 | 0.030 |
Why?
|
Cell Self Renewal | 1 | 2015 | 69 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 1999 | 1049 | 0.030 |
Why?
|
Transforming Growth Factor alpha | 1 | 1994 | 94 | 0.030 |
Why?
|
Administration, Oral | 3 | 2000 | 1603 | 0.030 |
Why?
|
Axons | 1 | 2018 | 441 | 0.030 |
Why?
|
Antigens, Neoplasm | 3 | 2005 | 1580 | 0.030 |
Why?
|
Organoids | 1 | 2017 | 332 | 0.030 |
Why?
|
Insulin-Secreting Cells | 1 | 2016 | 160 | 0.030 |
Why?
|
Behavior, Animal | 1 | 2018 | 750 | 0.030 |
Why?
|
Crosses, Genetic | 2 | 2009 | 251 | 0.030 |
Why?
|
Endoplasmic Reticulum | 1 | 2016 | 326 | 0.030 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2016 | 320 | 0.030 |
Why?
|
Telomerase | 1 | 1997 | 546 | 0.030 |
Why?
|
Medication Adherence | 1 | 2019 | 512 | 0.030 |
Why?
|
Retina | 1 | 1998 | 539 | 0.030 |
Why?
|
Telomere | 1 | 1997 | 548 | 0.030 |
Why?
|
Fluorescence | 1 | 2014 | 198 | 0.030 |
Why?
|
Retroviridae | 1 | 2015 | 373 | 0.030 |
Why?
|
Radiation-Sensitizing Agents | 2 | 1993 | 366 | 0.030 |
Why?
|
Hospital Bed Capacity, 500 and over | 1 | 1993 | 19 | 0.030 |
Why?
|
Retinoids | 2 | 2006 | 149 | 0.030 |
Why?
|
Calcitonin | 1 | 1995 | 182 | 0.030 |
Why?
|
Hospitals, Military | 1 | 1993 | 12 | 0.030 |
Why?
|
Lentivirus | 1 | 2014 | 164 | 0.030 |
Why?
|
Protein Binding | 2 | 2017 | 3477 | 0.030 |
Why?
|
Virion | 1 | 2015 | 186 | 0.030 |
Why?
|
Osteoclasts | 1 | 1995 | 155 | 0.030 |
Why?
|
Alveolar Epithelial Cells | 1 | 2014 | 51 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2018 | 678 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2014 | 217 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2000 | 1427 | 0.030 |
Why?
|
Antipsychotic Agents | 1 | 2018 | 428 | 0.030 |
Why?
|
Pyrimidines | 2 | 2017 | 3662 | 0.030 |
Why?
|
Chromatids | 1 | 2014 | 84 | 0.030 |
Why?
|
Cell Line | 4 | 2007 | 5336 | 0.030 |
Why?
|
Etoposide | 2 | 2014 | 905 | 0.030 |
Why?
|
Synapses | 1 | 2018 | 556 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 2 | 2014 | 2616 | 0.030 |
Why?
|
Random Allocation | 2 | 2011 | 740 | 0.030 |
Why?
|
Mice, Mutant Strains | 2 | 2009 | 651 | 0.030 |
Why?
|
Topotecan | 3 | 2000 | 248 | 0.030 |
Why?
|
Capecitabine | 1 | 2014 | 390 | 0.030 |
Why?
|
Conjunctiva | 1 | 1995 | 225 | 0.030 |
Why?
|
Recurrence | 4 | 2012 | 4872 | 0.030 |
Why?
|
Seminal Vesicles | 1 | 2013 | 149 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 1998 | 959 | 0.030 |
Why?
|
Azepines | 1 | 2014 | 134 | 0.030 |
Why?
|
Mexico | 3 | 2000 | 275 | 0.030 |
Why?
|
Alternative Splicing | 1 | 1996 | 612 | 0.030 |
Why?
|
Epidemiologic Factors | 1 | 2013 | 13 | 0.030 |
Why?
|
Hospitals, Teaching | 1 | 1993 | 125 | 0.030 |
Why?
|
Polyethylene Glycols | 1 | 1997 | 651 | 0.030 |
Why?
|
Integrin alpha6 | 1 | 2013 | 18 | 0.030 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 734 | 0.030 |
Why?
|
Hospitals, Public | 1 | 2013 | 60 | 0.030 |
Why?
|
Heart Diseases | 2 | 1996 | 718 | 0.030 |
Why?
|
Personal Satisfaction | 1 | 2013 | 124 | 0.030 |
Why?
|
AC133 Antigen | 1 | 2013 | 107 | 0.030 |
Why?
|
Neovascularization, Pathologic | 2 | 2010 | 1581 | 0.030 |
Why?
|
NF-kappa B | 2 | 2013 | 1560 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2016 | 1320 | 0.030 |
Why?
|
Allografts | 1 | 2015 | 686 | 0.030 |
Why?
|
Remission Induction | 1 | 2019 | 3648 | 0.030 |
Why?
|
Epigenomics | 1 | 2014 | 273 | 0.030 |
Why?
|
Proteolysis | 1 | 2014 | 377 | 0.030 |
Why?
|
Collagen | 1 | 2015 | 710 | 0.030 |
Why?
|
Iodine Radioisotopes | 1 | 1994 | 386 | 0.030 |
Why?
|
Base Sequence | 5 | 2002 | 5424 | 0.030 |
Why?
|
Colonic Neoplasms | 2 | 1999 | 1427 | 0.030 |
Why?
|
Liver Cirrhosis | 1 | 2000 | 1043 | 0.030 |
Why?
|
Ketosis | 1 | 2012 | 15 | 0.030 |
Why?
|
Cell Nucleolus | 1 | 2012 | 101 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 2325 | 0.030 |
Why?
|
Gene Regulatory Networks | 1 | 2016 | 681 | 0.030 |
Why?
|
Escherichia coli | 1 | 2019 | 1302 | 0.030 |
Why?
|
Ploidies | 1 | 2012 | 250 | 0.030 |
Why?
|
Phospholipid Ethers | 1 | 1992 | 14 | 0.030 |
Why?
|
Salivary Gland Neoplasms | 1 | 1997 | 497 | 0.030 |
Why?
|
Enhancer Elements, Genetic | 1 | 2014 | 492 | 0.030 |
Why?
|
Blood Proteins | 1 | 1993 | 299 | 0.030 |
Why?
|
Droperidol | 1 | 1992 | 3 | 0.030 |
Why?
|
Peritoneal Cavity | 1 | 1992 | 58 | 0.030 |
Why?
|
Diphenhydramine | 1 | 1992 | 20 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2014 | 498 | 0.030 |
Why?
|
Antifungal Agents | 1 | 1998 | 875 | 0.030 |
Why?
|
Antigens, CD1 | 1 | 2012 | 48 | 0.030 |
Why?
|
Alkaloids | 1 | 1992 | 84 | 0.020 |
Why?
|
Metoclopramide | 1 | 1992 | 34 | 0.020 |
Why?
|
9,10-Dimethyl-1,2-benzanthracene | 2 | 2002 | 128 | 0.020 |
Why?
|
Gene Knockout Techniques | 1 | 2013 | 269 | 0.020 |
Why?
|
Lorazepam | 1 | 1992 | 40 | 0.020 |
Why?
|
Hyperammonemia | 1 | 2012 | 66 | 0.020 |
Why?
|
Menstrual Cycle | 1 | 1992 | 62 | 0.020 |
Why?
|
Nuclear Receptor Coactivator 1 | 1 | 2013 | 262 | 0.020 |
Why?
|
Epithelium | 2 | 2009 | 773 | 0.020 |
Why?
|
Cefoxitin | 1 | 1991 | 6 | 0.020 |
Why?
|
Avian Leukosis Virus | 1 | 2011 | 15 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2013 | 521 | 0.020 |
Why?
|
Mammary Glands, Human | 1 | 2013 | 183 | 0.020 |
Why?
|
Spindle Apparatus | 1 | 2011 | 111 | 0.020 |
Why?
|
Tetradecanoylphorbol Acetate | 2 | 2004 | 248 | 0.020 |
Why?
|
rho-Specific Guanine Nucleotide Dissociation Inhibitors | 1 | 2011 | 9 | 0.020 |
Why?
|
Inflammation | 2 | 2015 | 2491 | 0.020 |
Why?
|
Binding Sites | 1 | 2016 | 2248 | 0.020 |
Why?
|
Genome-Wide Association Study | 2 | 2011 | 2348 | 0.020 |
Why?
|
rho Guanine Nucleotide Dissociation Inhibitor alpha | 1 | 2011 | 13 | 0.020 |
Why?
|
Nuclear Receptor Coactivator 2 | 1 | 2013 | 207 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2011 | 101 | 0.020 |
Why?
|
Sumoylation | 1 | 2011 | 81 | 0.020 |
Why?
|
Receptor, ErbB-3 | 1 | 2011 | 126 | 0.020 |
Why?
|
Blood Cells | 2 | 1988 | 129 | 0.020 |
Why?
|
Gene Order | 1 | 2011 | 108 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2014 | 657 | 0.020 |
Why?
|
Vulnerable Populations | 1 | 2013 | 187 | 0.020 |
Why?
|
Multiple Myeloma | 2 | 2003 | 2281 | 0.020 |
Why?
|
Preoperative Care | 1 | 1997 | 1552 | 0.020 |
Why?
|
Focal Adhesion Kinase 1 | 1 | 2011 | 116 | 0.020 |
Why?
|
Cell-Matrix Junctions | 1 | 2010 | 9 | 0.020 |
Why?
|
Pancreatic Diseases | 1 | 2011 | 113 | 0.020 |
Why?
|
Sialic Acids | 1 | 1990 | 24 | 0.020 |
Why?
|
cdc42 GTP-Binding Protein | 1 | 2010 | 46 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2015 | 597 | 0.020 |
Why?
|
Elective Surgical Procedures | 3 | 1997 | 249 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 2 | 2009 | 2207 | 0.020 |
Why?
|
Interleukin-1 | 1 | 1992 | 471 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2014 | 676 | 0.020 |
Why?
|
Antigen-Presenting Cells | 1 | 2012 | 286 | 0.020 |
Why?
|
Antiemetics | 1 | 1992 | 122 | 0.020 |
Why?
|
Polyribosomes | 1 | 2010 | 33 | 0.020 |
Why?
|
Pyrroles | 1 | 2014 | 587 | 0.020 |
Why?
|
Amylases | 1 | 2010 | 65 | 0.020 |
Why?
|
Insurance Coverage | 1 | 2013 | 274 | 0.020 |
Why?
|
Odds Ratio | 2 | 2011 | 2296 | 0.020 |
Why?
|
Antigens, Tumor-Associated, Carbohydrate | 1 | 1990 | 118 | 0.020 |
Why?
|
Cyclophosphamide | 2 | 2010 | 3242 | 0.020 |
Why?
|
Hypoglycemia | 1 | 2012 | 219 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2012 | 701 | 0.020 |
Why?
|
Point Mutation | 1 | 1993 | 788 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2015 | 1726 | 0.020 |
Why?
|
Educational Measurement | 1 | 2013 | 396 | 0.020 |
Why?
|
rhoA GTP-Binding Protein | 1 | 2010 | 83 | 0.020 |
Why?
|
Epirubicin | 1 | 2010 | 159 | 0.020 |
Why?
|
Pedigree | 2 | 2006 | 2043 | 0.020 |
Why?
|
Gene Dosage | 2 | 2008 | 823 | 0.020 |
Why?
|
Insulin | 1 | 2016 | 1471 | 0.020 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2010 | 110 | 0.020 |
Why?
|
Blood Loss, Surgical | 1 | 2011 | 294 | 0.020 |
Why?
|
Radiation, Ionizing | 1 | 2010 | 190 | 0.020 |
Why?
|
Mammography | 1 | 2016 | 1052 | 0.020 |
Why?
|
Claudin-1 | 1 | 2009 | 31 | 0.020 |
Why?
|
rho GTP-Binding Proteins | 1 | 2011 | 178 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2011 | 589 | 0.020 |
Why?
|
Hormones | 2 | 1988 | 284 | 0.020 |
Why?
|
Axilla | 3 | 1999 | 933 | 0.020 |
Why?
|
CpG Islands | 1 | 2012 | 671 | 0.020 |
Why?
|
Protein Kinases | 2 | 2008 | 897 | 0.020 |
Why?
|
Ribosomal Protein S6 Kinases | 1 | 2009 | 123 | 0.020 |
Why?
|
Lymphoma, AIDS-Related | 1 | 2009 | 69 | 0.020 |
Why?
|
Protein Phosphatase 2C | 1 | 2009 | 86 | 0.020 |
Why?
|
Thrombospondin 1 | 1 | 2009 | 51 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2011 | 309 | 0.020 |
Why?
|
Epiregulin | 1 | 2009 | 14 | 0.020 |
Why?
|
Gene Deletion | 2 | 2006 | 1473 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2009 | 336 | 0.020 |
Why?
|
Chromatin | 1 | 2014 | 1042 | 0.020 |
Why?
|
Quality of Life | 2 | 2017 | 4772 | 0.020 |
Why?
|
Glycoproteins | 1 | 2013 | 778 | 0.020 |
Why?
|
G-Quadruplexes | 1 | 2009 | 20 | 0.020 |
Why?
|
Lipid Metabolism | 1 | 2012 | 474 | 0.020 |
Why?
|
Celecoxib | 1 | 2009 | 198 | 0.020 |
Why?
|
Recombinant Proteins | 3 | 2005 | 3023 | 0.020 |
Why?
|
Canada | 1 | 1990 | 439 | 0.020 |
Why?
|
Hematopoietic System | 1 | 1988 | 26 | 0.020 |
Why?
|
Area Under Curve | 1 | 2010 | 729 | 0.020 |
Why?
|
Prevalence | 3 | 2002 | 3351 | 0.020 |
Why?
|
Pyridones | 1 | 2011 | 360 | 0.020 |
Why?
|
Sampling Studies | 1 | 1988 | 170 | 0.020 |
Why?
|
Parity | 1 | 2008 | 136 | 0.020 |
Why?
|
Cytoplasm | 1 | 2010 | 699 | 0.020 |
Why?
|
Cell Transplantation | 1 | 2008 | 86 | 0.020 |
Why?
|
RNA-Binding Proteins | 1 | 2014 | 1017 | 0.020 |
Why?
|
Quality Control | 1 | 1990 | 460 | 0.020 |
Why?
|
Pancreaticojejunostomy | 1 | 2008 | 14 | 0.020 |
Why?
|
Medroxyprogesterone Acetate | 1 | 1988 | 49 | 0.020 |
Why?
|
Antibodies | 1 | 2011 | 806 | 0.020 |
Why?
|
Hypovolemia | 1 | 2008 | 12 | 0.020 |
Why?
|
Phosphoprotein Phosphatases | 1 | 2009 | 223 | 0.020 |
Why?
|
Blood Transfusion | 1 | 2011 | 581 | 0.020 |
Why?
|
Binding, Competitive | 1 | 2008 | 327 | 0.020 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2010 | 327 | 0.020 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2009 | 290 | 0.020 |
Why?
|
Quality Indicators, Health Care | 1 | 2011 | 351 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2009 | 224 | 0.020 |
Why?
|
Microfilament Proteins | 2 | 2003 | 495 | 0.020 |
Why?
|
Histiocytes | 1 | 1988 | 94 | 0.020 |
Why?
|
Pregnancy, Animal | 1 | 2008 | 102 | 0.020 |
Why?
|
Nucleotidyltransferases | 1 | 2008 | 96 | 0.020 |
Why?
|
Benzimidazoles | 1 | 2011 | 437 | 0.020 |
Why?
|
Pharmacogenetics | 1 | 2009 | 267 | 0.020 |
Why?
|
Genetic Vectors | 3 | 2001 | 1856 | 0.020 |
Why?
|
Pulmonary Alveoli | 1 | 2009 | 220 | 0.020 |
Why?
|
Antigens, CD | 1 | 2013 | 1411 | 0.020 |
Why?
|
Salvage Therapy | 1 | 1996 | 2122 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2012 | 1181 | 0.020 |
Why?
|
Dendritic Cells | 1 | 2014 | 1110 | 0.020 |
Why?
|
Unnecessary Procedures | 1 | 2008 | 101 | 0.020 |
Why?
|
Kinetics | 2 | 2003 | 2186 | 0.020 |
Why?
|
Myocardium | 1 | 2013 | 1116 | 0.020 |
Why?
|
Computational Biology | 1 | 2014 | 1292 | 0.020 |
Why?
|
Bacterial Infections | 1 | 1991 | 508 | 0.020 |
Why?
|
Patched Receptors | 1 | 2007 | 48 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2010 | 1688 | 0.020 |
Why?
|
Epidermal Growth Factor | 1 | 2009 | 439 | 0.020 |
Why?
|
Esophagoscopy | 1 | 2009 | 306 | 0.020 |
Why?
|
Patched-1 Receptor | 1 | 2007 | 50 | 0.020 |
Why?
|
Choline Dehydrogenase | 1 | 2006 | 2 | 0.020 |
Why?
|
Peptides | 1 | 2013 | 1503 | 0.020 |
Why?
|
Phagocytosis | 1 | 1988 | 292 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 2011 | 809 | 0.020 |
Why?
|
Receptors, Interleukin-17 | 1 | 2006 | 26 | 0.020 |
Why?
|
Dual Specificity Phosphatase 6 | 1 | 2006 | 4 | 0.020 |
Why?
|
Dexamethasone | 1 | 1992 | 1507 | 0.020 |
Why?
|
Genetic Variation | 1 | 1995 | 2165 | 0.020 |
Why?
|
United Kingdom | 1 | 2007 | 287 | 0.020 |
Why?
|
Lipids | 1 | 1990 | 654 | 0.020 |
Why?
|
Comorbidity | 1 | 2013 | 2389 | 0.020 |
Why?
|
Neoplasms, Multiple Primary | 1 | 1990 | 554 | 0.020 |
Why?
|
Poly(ADP-ribose) Polymerases | 2 | 2003 | 315 | 0.020 |
Why?
|
Tumor Burden | 1 | 2012 | 2031 | 0.020 |
Why?
|
beta Catenin | 1 | 2010 | 681 | 0.020 |
Why?
|
Resuscitation | 1 | 2009 | 274 | 0.020 |
Why?
|
RNA, Bacterial | 1 | 2006 | 84 | 0.020 |
Why?
|
Postoperative Care | 1 | 1990 | 728 | 0.020 |
Why?
|
Metabolism | 1 | 2006 | 50 | 0.020 |
Why?
|
Image Enhancement | 1 | 2010 | 553 | 0.020 |
Why?
|
DNA, Antisense | 1 | 2005 | 44 | 0.020 |
Why?
|
Cell Membrane | 1 | 2009 | 874 | 0.020 |
Why?
|
Homozygote | 1 | 2008 | 772 | 0.020 |
Why?
|
Caspase 3 | 1 | 2007 | 472 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2010 | 1001 | 0.020 |
Why?
|
Retinoic Acid 4-Hydroxylase | 1 | 2005 | 17 | 0.020 |
Why?
|
Neuregulin-1 | 1 | 2005 | 89 | 0.020 |
Why?
|
Body Mass Index | 1 | 2013 | 2238 | 0.020 |
Why?
|
HIV-1 | 1 | 2009 | 639 | 0.020 |
Why?
|
In Situ Nick-End Labeling | 1 | 2005 | 436 | 0.020 |
Why?
|
Dimerization | 1 | 2005 | 311 | 0.020 |
Why?
|
Aneuploidy | 2 | 1997 | 377 | 0.020 |
Why?
|
Genes, Homeobox | 1 | 2005 | 142 | 0.020 |
Why?
|
Interleukin-2 | 1 | 1988 | 889 | 0.020 |
Why?
|
Enzymes | 1 | 2005 | 69 | 0.020 |
Why?
|
Cholesterol | 1 | 2008 | 658 | 0.020 |
Why?
|
Embryo, Mammalian | 1 | 2008 | 744 | 0.020 |
Why?
|
Clone Cells | 2 | 1999 | 587 | 0.020 |
Why?
|
Drug Resistance, Multiple | 1 | 2005 | 221 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2011 | 1577 | 0.020 |
Why?
|
Ethics, Research | 1 | 2005 | 67 | 0.020 |
Why?
|
E1A-Associated p300 Protein | 1 | 2005 | 97 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2015 | 1415 | 0.010 |
Why?
|
Drosophila melanogaster | 1 | 2010 | 866 | 0.010 |
Why?
|
Leukemia | 1 | 1993 | 1719 | 0.010 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 230 | 0.010 |
Why?
|
Biofilms | 1 | 2006 | 205 | 0.010 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2005 | 198 | 0.010 |
Why?
|
DNA Copy Number Variations | 1 | 2011 | 1552 | 0.010 |
Why?
|
Substrate Specificity | 1 | 2005 | 579 | 0.010 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2005 | 212 | 0.010 |
Why?
|
Imidazoles | 1 | 2009 | 1056 | 0.010 |
Why?
|
Neovascularization, Physiologic | 1 | 2005 | 341 | 0.010 |
Why?
|
Luciferases | 1 | 2004 | 459 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2009 | 2586 | 0.010 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2004 | 507 | 0.010 |
Why?
|
Patient Care Planning | 1 | 2005 | 302 | 0.010 |
Why?
|
Amino Acid Sequence | 2 | 2004 | 4561 | 0.010 |
Why?
|
Multigene Family | 1 | 2004 | 469 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2004 | 558 | 0.010 |
Why?
|
Culture Media, Serum-Free | 1 | 2002 | 80 | 0.010 |
Why?
|
Sp3 Transcription Factor | 1 | 2002 | 15 | 0.010 |
Why?
|
Cysteine Proteinase Inhibitors | 1 | 2003 | 94 | 0.010 |
Why?
|
Cyclooxygenase 2 | 1 | 2005 | 494 | 0.010 |
Why?
|
Integrases | 1 | 2004 | 256 | 0.010 |
Why?
|
Caspase 8 | 1 | 2003 | 146 | 0.010 |
Why?
|
Myocytes, Cardiac | 1 | 2008 | 684 | 0.010 |
Why?
|
Ligands | 1 | 2005 | 1014 | 0.010 |
Why?
|
Acetyltransferases | 1 | 2003 | 146 | 0.010 |
Why?
|
Carbon Dioxide | 1 | 2004 | 321 | 0.010 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2002 | 201 | 0.010 |
Why?
|
Virulence | 1 | 2003 | 351 | 0.010 |
Why?
|
Caspase 9 | 1 | 2003 | 187 | 0.010 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 1994 | 589 | 0.010 |
Why?
|
Reproductive History | 1 | 2001 | 23 | 0.010 |
Why?
|
Respiratory Tract Diseases | 1 | 2002 | 111 | 0.010 |
Why?
|
Genetic Carrier Screening | 1 | 2002 | 101 | 0.010 |
Why?
|
Injections, Intralesional | 1 | 2002 | 166 | 0.010 |
Why?
|
G1 Phase | 1 | 2003 | 305 | 0.010 |
Why?
|
beta-Galactosidase | 1 | 2002 | 271 | 0.010 |
Why?
|
Lymph Node Excision | 1 | 1990 | 2056 | 0.010 |
Why?
|
Cloning, Molecular | 2 | 1995 | 1430 | 0.010 |
Why?
|
Ganciclovir | 1 | 2002 | 194 | 0.010 |
Why?
|
Growth Substances | 1 | 2002 | 325 | 0.010 |
Why?
|
Bromodeoxyuridine | 1 | 2001 | 129 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 1990 | 3999 | 0.010 |
Why?
|
Thymidine Kinase | 1 | 2002 | 223 | 0.010 |
Why?
|
Stomach Neoplasms | 1 | 1994 | 2256 | 0.010 |
Why?
|
Viral Proteins | 1 | 2004 | 491 | 0.010 |
Why?
|
Stem Cell Transplantation | 1 | 2008 | 1413 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-yes | 1 | 2001 | 23 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2004 | 1472 | 0.010 |
Why?
|
Benzoates | 1 | 2002 | 128 | 0.010 |
Why?
|
Medical Records | 1 | 2002 | 442 | 0.010 |
Why?
|
Chloramphenicol O-Acetyltransferase | 1 | 2000 | 136 | 0.010 |
Why?
|
Histone Acetyltransferases | 1 | 2003 | 433 | 0.010 |
Why?
|
Mice, Inbred Strains | 1 | 2001 | 559 | 0.010 |
Why?
|
Pentose Phosphate Pathway | 1 | 2000 | 71 | 0.010 |
Why?
|
Food Deprivation | 1 | 2000 | 48 | 0.010 |
Why?
|
Antigens, Polyomavirus Transforming | 1 | 2000 | 146 | 0.010 |
Why?
|
Lipid Peroxidation | 1 | 2000 | 161 | 0.010 |
Why?
|
Inhibitory Concentration 50 | 1 | 2000 | 285 | 0.010 |
Why?
|
Hepatitis A Antibodies | 1 | 1999 | 9 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2010 | 4360 | 0.010 |
Why?
|
Superoxide Dismutase | 1 | 2000 | 264 | 0.010 |
Why?
|
RNA | 1 | 2004 | 1063 | 0.010 |
Why?
|
Blotting, Northern | 1 | 2000 | 723 | 0.010 |
Why?
|
Glutathione Transferase | 1 | 2000 | 367 | 0.010 |
Why?
|
Brain | 1 | 2013 | 4210 | 0.010 |
Why?
|
HSP27 Heat-Shock Proteins | 1 | 1999 | 33 | 0.010 |
Why?
|
Topoisomerase II Inhibitors | 1 | 1999 | 55 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2003 | 1376 | 0.010 |
Why?
|
DNA Fragmentation | 1 | 1999 | 205 | 0.010 |
Why?
|
HT29 Cells | 1 | 1999 | 155 | 0.010 |
Why?
|
Receptors, Somatomedin | 1 | 1999 | 72 | 0.010 |
Why?
|
Pemetrexed | 1 | 1999 | 100 | 0.010 |
Why?
|
Urban Population | 1 | 2000 | 279 | 0.010 |
Why?
|
Laparoscopy | 1 | 2008 | 1301 | 0.010 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 222 | 0.010 |
Why?
|
Molecular Chaperones | 1 | 1999 | 266 | 0.010 |
Why?
|
Nuclear Receptor Co-Repressor 1 | 1 | 1998 | 65 | 0.010 |
Why?
|
Drug Resistance, Microbial | 1 | 1998 | 242 | 0.010 |
Why?
|
Butyrates | 1 | 1998 | 56 | 0.010 |
Why?
|
Half-Life | 1 | 1998 | 269 | 0.010 |
Why?
|
Birth Weight | 1 | 1999 | 354 | 0.010 |
Why?
|
Energy Intake | 1 | 2000 | 523 | 0.010 |
Why?
|
Utilization Review | 1 | 1997 | 52 | 0.010 |
Why?
|
Software | 1 | 2004 | 1355 | 0.010 |
Why?
|
Intestinal Absorption | 1 | 1998 | 205 | 0.010 |
Why?
|
Hospitals, Urban | 1 | 1997 | 98 | 0.010 |
Why?
|
Rhabdomyosarcoma | 1 | 2000 | 340 | 0.010 |
Why?
|
Anorexia | 1 | 1998 | 147 | 0.010 |
Why?
|
Isoenzymes | 1 | 1999 | 650 | 0.010 |
Why?
|
Insurance, Health, Reimbursement | 1 | 1997 | 67 | 0.010 |
Why?
|
Hospitals, University | 1 | 1997 | 218 | 0.010 |
Why?
|
Immunoradiometric Assay | 1 | 1996 | 6 | 0.010 |
Why?
|
Adenoviridae | 1 | 2002 | 1496 | 0.010 |
Why?
|
Hepatitis B | 1 | 1999 | 273 | 0.010 |
Why?
|
Densitometry | 1 | 1996 | 51 | 0.010 |
Why?
|
Loperamide | 1 | 1996 | 13 | 0.010 |
Why?
|
Autoradiography | 1 | 1996 | 154 | 0.010 |
Why?
|
Orthodontics, Corrective | 1 | 1996 | 3 | 0.010 |
Why?
|
Ascites | 1 | 1997 | 212 | 0.010 |
Why?
|
Mandibular Advancement | 1 | 1996 | 6 | 0.010 |
Why?
|
Antidiarrheals | 1 | 1996 | 36 | 0.010 |
Why?
|
Sarcoma, Ewing | 1 | 2000 | 428 | 0.010 |
Why?
|
Micropore Filters | 1 | 1995 | 9 | 0.010 |
Why?
|
Cephalometry | 1 | 1996 | 46 | 0.010 |
Why?
|
Antigens, Viral | 1 | 1998 | 518 | 0.010 |
Why?
|
Metaphase | 1 | 1995 | 124 | 0.010 |
Why?
|
Staining and Labeling | 1 | 1997 | 434 | 0.010 |
Why?
|
Nausea | 1 | 1998 | 540 | 0.010 |
Why?
|
Cellulose | 1 | 1995 | 24 | 0.010 |
Why?
|
Range of Motion, Articular | 1 | 1996 | 112 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 1999 | 1655 | 0.010 |
Why?
|
Carboplatin | 1 | 1999 | 879 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2001 | 2357 | 0.010 |
Why?
|
Respiratory Function Tests | 1 | 1996 | 354 | 0.010 |
Why?
|
Metallothionein | 1 | 1994 | 33 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 1998 | 766 | 0.010 |
Why?
|
Microscopy, Electron, Scanning | 1 | 1995 | 240 | 0.010 |
Why?
|
Health Expenditures | 1 | 1997 | 202 | 0.010 |
Why?
|
Hospitals, Veterans | 1 | 1997 | 369 | 0.010 |
Why?
|
Antiviral Agents | 1 | 2002 | 1251 | 0.010 |
Why?
|
Histones | 1 | 2002 | 1512 | 0.010 |
Why?
|
Neuroblastoma | 1 | 2000 | 705 | 0.010 |
Why?
|
Calcitriol | 1 | 1995 | 134 | 0.010 |
Why?
|
Culture Media, Conditioned | 1 | 1994 | 254 | 0.010 |
Why?
|
Depression, Chemical | 1 | 1994 | 57 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 1992 | 5566 | 0.010 |
Why?
|
Liver Neoplasms | 2 | 1988 | 4814 | 0.010 |
Why?
|
Stimulation, Chemical | 1 | 1994 | 108 | 0.010 |
Why?
|
Isomerism | 1 | 1994 | 65 | 0.010 |
Why?
|
Hemoglobins | 1 | 1996 | 480 | 0.010 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 1 | 1993 | 30 | 0.010 |
Why?
|
Rabbits | 1 | 1995 | 1012 | 0.010 |
Why?
|
Bone Marrow | 2 | 1995 | 2437 | 0.010 |
Why?
|
Hepatitis C | 1 | 1999 | 547 | 0.010 |
Why?
|
Least-Squares Analysis | 1 | 1993 | 66 | 0.010 |
Why?
|
Precipitin Tests | 1 | 1993 | 349 | 0.010 |
Why?
|
Neutropenia | 1 | 1998 | 1006 | 0.010 |
Why?
|
Codon | 1 | 1994 | 261 | 0.010 |
Why?
|
Body Weight | 1 | 1998 | 1306 | 0.010 |
Why?
|
Radiotherapy, Adjuvant | 1 | 1998 | 2269 | 0.010 |
Why?
|
Tetrahydrouridine | 1 | 1992 | 6 | 0.010 |
Why?
|
Deamination | 1 | 1992 | 13 | 0.010 |
Why?
|
Diarrhea | 1 | 1996 | 712 | 0.010 |
Why?
|
Oligonucleotides, Antisense | 1 | 1993 | 255 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2008 | 7779 | 0.010 |
Why?
|
Medicare | 1 | 1997 | 925 | 0.010 |
Why?
|
Genome | 1 | 1995 | 690 | 0.010 |
Why?
|
Monocytes | 1 | 1995 | 779 | 0.010 |
Why?
|
Bone Marrow Cells | 1 | 1995 | 965 | 0.010 |
Why?
|
Pentoxifylline | 1 | 1990 | 38 | 0.010 |
Why?
|
Caffeine | 1 | 1990 | 96 | 0.010 |
Why?
|
Exons | 1 | 1994 | 1381 | 0.010 |
Why?
|
Carcinoma, Small Cell | 1 | 1992 | 427 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2002 | 2209 | 0.010 |
Why?
|
Graft vs Host Disease | 1 | 2000 | 2808 | 0.010 |
Why?
|
Vaccinia virus | 1 | 1988 | 85 | 0.000 |
Why?
|
Histiocytic Sarcoma | 1 | 1988 | 16 | 0.000 |
Why?
|
Adenosine Triphosphate | 1 | 1990 | 568 | 0.000 |
Why?
|
Oxygen | 1 | 1993 | 790 | 0.000 |
Why?
|
Alcohol Drinking | 1 | 1991 | 600 | 0.000 |
Why?
|
Transfusion Reaction | 1 | 1988 | 101 | 0.000 |
Why?
|
Surgical Wound Infection | 1 | 1991 | 480 | 0.000 |
Why?
|
Haiti | 1 | 1987 | 10 | 0.000 |
Why?
|
Sex Factors | 1 | 1991 | 2170 | 0.000 |
Why?
|
Spleen | 1 | 1988 | 724 | 0.000 |
Why?
|
Viral Vaccines | 1 | 1988 | 359 | 0.000 |
Why?
|
Sarcoma, Kaposi | 1 | 1987 | 190 | 0.000 |
Why?
|
Surgical Procedures, Operative | 1 | 1988 | 356 | 0.000 |
Why?
|
Veterans | 1 | 1996 | 1735 | 0.000 |
Why?
|
Benzamides | 1 | 1990 | 1878 | 0.000 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 1987 | 340 | 0.000 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2000 | 7009 | 0.000 |
Why?
|
Palliative Care | 1 | 1987 | 2173 | 0.000 |
Why?
|
Immunotherapy | 1 | 1988 | 3553 | 0.000 |
Why?
|
Carcinoma, Hepatocellular | 1 | 1987 | 2172 | 0.000 |
Why?
|